More about Abbott India Limited
Fundamentals for Abbott India Limited
Regulatory Filings for Abbott India Limited
Defence Profits Reach Dharavi's Machinists
From COVID Debt to Green Despair: Industrial Discharge Is Destroying India’s Last Prawn Nurseries
The Hidden Cost of India's Electronics Assembly Push: A 40% E-Waste Surge and the Death of Affordable Repair
The Wedding Loan Trap: How India’s Microfinance Boom Turned Housewives Into Ghost Borrowers and Temple Brass Into EMI Cash
Fundamentals for Abbott India Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It provides anti-infective, cardio-diabeto, hepatology, hormones, neuro-psychiat, hepatic, gennext, and consumer care products. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited.
Revenue projections:
ABBOTINDIA's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.
Financial Ratios:
| currentRatio | 0.00000 |
|---|---|
| forwardPE | 31.33993 |
| debtToEquity | 4.54900 |
| earningsGrowth | 0.04200 |
| revenueGrowth | 0.06800 |
| grossMargins | 0.46409 |
| operatingMargins | 0.25794 |
| trailingEps | 717.27000 |
| forwardEps | 810.78674 |
Abbott India Limited's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.
ABBOTINDIA's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that ABBOTINDIA's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.
Price projections:
ABBOTINDIA's present price, in comparison to its projections, indicates no evident risks or opportunities. This balanced scenario suggests a steady environment, where investors might choose to wait for more definitive indicators before altering their strategies.
Recommendation changes over time:
Analysts' buy bias for ABBOTINDIA signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to ABBOTINDIA, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
From Lifesaving Drugs to Sick Units: The Hidden Energy Crisis Inside India’s Pharma Clusters
From Price Pressures to Profit Power: The MSME Playbook Redefining India’s Economy
₹90 Crore Bet Signals a Massive Shift in India’s Rural Economy